ANI Pharmaceuticals (ANIP)

• Market cap: $1.14B
• 1 day: -0.09%
• 5 days: -3.25%
• 1 month: -7.64%
• 3 months: -7.45%
• 6 months: -13.79%
• Year to date: -5.30%
• 1 year: -2.08%
• 5 years: -16.16%
• 10 years: -1.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 642

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

93% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 44

18% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 33

16.75% more ownership

Funds ownership: 73.45% [Q2] → 90.19% (+16.75%) [Q3]

16% more capital invested

Capital invested by funds: $980M [Q2] → $1.14B (+$157M) [Q3]

3% more funds holding

Funds holding: 201 [Q2] → 207 (+6) [Q3]

9% less call options, than puts

Call options by funds: $721K | Put options by funds: $793K

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $62 14% upside
• Avg. target: $76 40% upside
• High target: $94 74% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Leerink Partners Faisal Khurshid 33% 1-year accuracy 3 / 9 met price target	48% upside $80	Outperform Initiated	11 Dec 2024
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target	74% upside $94	Buy Reiterated	11 Nov 2024
Truist Securities Gregory Fraser 25% 1-year accuracy 1 / 4 met price target	14% upside $62	Hold Maintained	22 Oct 2024
Piper Sandler David Amsellem 46% 1-year accuracy 17 / 37 met price target	26% upside $68	Overweight Initiated	11 Oct 2024